Lasa Supergenerics is currently trading at Rs. 18.45, up by 0.30 points or 1.65% from its previous closing of Rs. 18.15 on the BSE.
The scrip opened at Rs. 18.15 and has touched a high and low of Rs. 18.45 and Rs. 18.00 respectively. So far 4550 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 36.10 on 04-Jan-2019 and a 52 week low of Rs. 9.48 on 06-Aug-2019.
Last one week high and low of the scrip stood at Rs. 18.90 and Rs. 17.90 respectively. The current market cap of the company is Rs. 75.04 crore.
The promoters holding in the company stood at 34.60%, while Institutions and Non-Institutions held NA% and 65.40% respectively.
Lasa Supergenerics has been granted patents for its key products for the period of 20 years. The company has been granted patents for ‘An improved process for the preparation of Methyl 5-(Propylthio)-1h-Benzo [D] Imidazol-2-Ylcarbanate’ and ‘Process for the preparation of Benzimidazole Derivative as Anthelmintic Agents.’ Till date the company has been successfully granted 6 patents and rest 2 are in pipeline.
Lasa Supergenerics, pioneer and amongst the leading players in the manufacturing of APIs in India through its catalyst chemistry expertise and fully backward integrated unit.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1489.75 |
Dr. Reddys Lab | 5999.35 |
Cipla | 1490.00 |
Zydus Lifesciences | 1047.30 |
Lupin | 1603.00 |
View more.. |